Innovations In Cell And Gene Therapy Manufacturing For 2023 And Beyond

As cell and gene therapies continue to gain traction in the greater pharmaceutical landscape, the challenges that define the larger advanced therapy ecosystem have likewise begun to exert more pressure for companies and clinical trial sponsors. From supply chain constraints to siloed data to characterization and development hurdles, the variables that may serve to limit scale for many advanced therapies are both diverse and profound.

However, these challenges exist alongside a number of opportunities, many of them tied to emerging research, new technology platforms, and increasing collaboration across the space. As these modalities continue to evolve in 2023 and beyond, the sector is poised to experience big advancements in key arenas, including for allogeneic cell therapies, non-viral vectors, and in vivo drug manufacturing and delivery. Likewise, many incumbent solutions, such as viral vectors and autologous cell therapies, are primed for continued optimization, paving the way for more efficacious, affordable treatments.